View Older Stories View More Recent Stories

Jul 11, 2022 07:15AM Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
Jul 8, 2022 02:59AM Sobi to license loncastuximab tesirine from ADC Therapeutics
Jul 8, 2022 02:00AM ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
Jul 1, 2022 07:15AM ADC Therapeutics SA (ADCT) Appoints Jean-Pierre Bizzari to its Board
Jul 1, 2022 07:15AM ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
Jun 29, 2022 07:43AM ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
Jun 13, 2022 07:15AM ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
Jun 10, 2022 05:33AM ADC Therapeutics SA (ADCT) Reports Phase 2 Results of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
Jun 10, 2022 03:00AM ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
Jun 1, 2022 07:15AM ADC Therapeutics to Present at the Jefferies Healthcare Conference
May 12, 2022 12:15PM ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 9, 2022 07:01AM ADC Therapeutics SA (ADCT) Announces CEO Transition
May 9, 2022 07:00AM ADC Therapeutics Announces CEO Transition
May 9, 2022 07:00AM ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 4, 2022 07:15AM ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 3, 2022 07:15AM ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
Apr 4, 2022 07:15AM ADC Therapeutics SA (ADCT) Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
Apr 4, 2022 07:15AM ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
Mar 17, 2022 08:40AM ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
Mar 3, 2022 07:00AM ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Mar 1, 2022 07:15AM ADC Therapeutics to Participate in Cowen’s 42nd Annual Health Care Conference
Feb 24, 2022 07:15AM ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
Feb 17, 2022 07:15AM ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
Feb 8, 2022 07:15AM ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
Feb 2, 2022 07:15AM ADC Therapeutics to Participate in Guggenheim Oncology Conference
Jan 20, 2022 07:15AM ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
Jan 18, 2022 05:39AM ADC Therapeutics SA (ADCT) Enters Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA in Japan
Jan 18, 2022 05:00AM ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
Nov 9, 2021 07:15AM ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
Nov 4, 2021 09:25AM ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
Nov 2, 2021 07:00AM ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
Oct 29, 2021 07:16AM ADC Therapeutics SA (ADCT) Announces EU Medicines Agency Validates its Marketing Authorization Application for ZYNLONTA
Oct 29, 2021 07:15AM ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
Oct 27, 2021 07:15AM ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
Sep 29, 2021 07:18AM Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma (ADCT)
Sep 29, 2021 07:15AM Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
Sep 27, 2021 07:15AM ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
Sep 23, 2021 07:15AM ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Sep 13, 2021 07:15AM ADC Therapeutics SA (ADCT) ZYNLONTA Receives Orphan Drug Designation in Europe
Sep 13, 2021 07:15AM ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
Sep 9, 2021 07:15AM ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
Sep 3, 2021 07:15AM ADC Therapeutics Announces Medical Leadership Transition
Aug 26, 2021 07:16AM ADC Therapeutics SA (ADCT) enters royalty purchase agreement with HealthCare Royalty Partners
Aug 26, 2021 07:15AM ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
Aug 3, 2021 07:00AM ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Jul 28, 2021 04:56PM ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
Jun 22, 2021 09:55AM ADC Therapeutics SA (ADCT) Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant
Jun 22, 2021 09:55AM ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
Jun 18, 2021 07:15AM ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
Jun 11, 2021 07:15AM ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
View More Recent Stories View Older Stories